Pharmaceutical company Braeburn Pharmaceuticals Inc reported on Wednesday the completion of USD110m mezzanine round of financing.
This financing was led by Wellington Capital Management. Other new investors participating in the financing include Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management, and Rock Springs Capital. Apple Tree Partners, the sole investor in Braeburn to date, participated.
According to the company, the proceeds will be used to continue to advance the US FDA approval process and commercialise CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder (OUD). According to the chair of the American Medical Association's Opioid Task Force, only 20% of those who need OUD treatment are receiving it.
Under the terms of the financing, Brian A. Markison has been named to Braeburn's board of directors, together with an additional nomination to be confirmed shortly.
Currently, Markison serves as the chief executive officer and chairman of Osmotica Holdings, SCSp and an Avista operating executive.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML